PYC — PYC Therapeutics Cashflow Statement
0.000.00%
- AU$703.71m
- AU$552.12m
- AU$26.17m
Annual cashflow statement for PYC Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Changes in Working Capital | 3.26 | 6.1 | 9.74 | 21.3 | 20.1 |
Other Operating Cash Flow | |||||
Cash from Operating Activities | -11.8 | -21.8 | -24.4 | -38.6 | -51.6 |
Capital Expenditures | -0.591 | -0.387 | -0.491 | -0.307 | -0.975 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -14.9 | 33.1 | 0.014 | 0 | — |
Change in Net Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -15.5 | 32.7 | -0.477 | -0.307 | -0.975 |
Financing Cash Flow Items | -2.29 | 0 | -0.976 | -1.57 | -6.8 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 38.6 | -0.182 | 11.4 | 90.2 | 139 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 11.2 | 10.7 | -13.5 | 51.3 | 86.2 |